B2M Reduction via RNAi for Cognitive Impairment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aging-associated cognitive impairments, characterized by structural and neurophysiological changes leading to cognitive decline and susceptibility to degenerative disorders, are not effectively addressed by existing technologies, with β-2 microglobulin (B2M) playing a role in impairing hippocampal-dependent cognitive function and adult neurogenesis.
Innovation Solution
Reducing B2M levels in mammals through methods such as RNAi agents, antisense molecules, or B2M-specific binding members to modulate B2M expression or activity, thereby mitigating the negative effects on cognitive function and neurogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If B2M levels are reduced to treat aging-associated impairments, then cognitive function and neurogenesis are enhanced, but existing technologies fail to effectively address aging-associated cognitive impairments
Solution Approach 1:
The patent employs RNA interference (RNAi) agents as intermediary molecules to reduce B2M expression. These small interfering RNAs (siRNAs) act as mediators between the therapeutic goal (reducing B2M) and the cellular machinery (transcription/translation), providing a targeted and effective treatment approach that overcomes the limitations of existing therapies.
Solution Approach 2:
The patent utilizes parameter changes in gene expression levels by introducing RNAi agents that specifically target B2M mRNA for degradation. This changes the concentration parameter of B2M protein in the system, reducing it to therapeutic levels while enhancing cognitive function and neurogenesis without the complexity of more invasive interventions.
2Duration of action of stationary object
If B2M levels are reduced through RNAi agents or antisense molecules, then cognitive decline is slowed or reversed, but the complexity of the intervention increases
Solution Approach 1:
The patent employs RNAi agents that provide continuous suppression of B2M expression through sustained reduction of B2M mRNA levels. This continuous action on gene expression ensures prolonged cognitive improvement and neurogenesis enhancement, maintaining therapeutic effects over extended periods without requiring frequent complex interventions.
Solution Approach 2:
The RNAi agents introduced in the patent utilize the cell's own RNA interference machinery to achieve sustained B2M suppression. Once introduced, these molecules are processed by endogenous Dicer enzymes and incorporated into RISC complexes, allowing the system to self-maintain the therapeutic effect through continuous cycles of mRNA degradation without requiring external re-intervention.
3Measurement precision
If B2M-specific binding members are used to modulate B2M activity, then hippocampal-dependent cognitive function is enhanced, but the specificity and precision of targeting B2M becomes more challenging
Solution Approach 1:
The patent employs RNAi agents that specifically target and extract B2M mRNA from the cellular pool through sequence-complementary binding. This extraction approach provides high specificity by directly removing the target mRNA molecules containing the B2M coding sequence, avoiding off-target effects while achieving precise modulation of B2M levels through highly specific nucleotide sequence recognition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The reduction of B2M levels effectively treats aging-associated impairments, including cognitive impairments, by enhancing hippocampal-dependent cognitive function and adult neurogenesis, slowing or reversing cognitive decline, and stabilizing or improving cognitive abilities.
Implementation Method 1
administering to the adult mammal an effective amount of a B2M modulatory agent, such as, but not limited to, an RNAi agent, an antisense molecule, a small molecule compound, a peptide, a protein, or an antibody
Implementation Method 2
administering to the adult mammal an effective amount of a B2M modulatory agent, such as, but not limited to, an RNAi agent, an antisense molecule, a small molecule compound, a peptide, a protein, or an antibody
Data Source
AI summary
Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include reducing the 2-microglobulin (B2M) level in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.